British pharmaceutical giant GlaxoSmithKline has reported that they have achieved an 80% response rate in volunteers receiving an experimental vaccine to combat the H5N1 avian influenza strain. Of importance is that the immune response was secondary to two relatively small doses of 3.8 micrograms of the antigen.
Copyright 2006 Insidesurgery.com